会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • Compound
    • 复合
    • US20100120789A1
    • 2010-05-13
    • US12554943
    • 2009-09-07
    • Nigel VickerXiangdong SuFabienne PraduaxMichael John ReedBarry Victor Lloyd Potter
    • Nigel VickerXiangdong SuFabienne PraduaxMichael John ReedBarry Victor Lloyd Potter
    • A61K31/497C07C233/00A61K31/165A61K31/4365C07D495/04C07D405/02C12Q1/32
    • C11D3/0073C11D3/2086C11D3/33C11D7/265C11D7/3245C11D11/0041
    • There is provided a compound having Formula I R1—Z—R2   Formula I wherein R1 is a group selected from optionally substituted fused polycyclic groups, substituted alkyl groups, branched alkyl groups, and optionally substituted cycloalkyl groups Z is a linker which is or comprises a carbonyl group or a isostere of a carbonyl group R2 is selected from optionally substituted aromatic rings and optionally substituted heterocyclic rings wherein (a) R2 is a 2-substituted thiophene group, and/or (b) Z is a group of the formula —C(═O)—CR3R4—X—(CR5R6)n-, wherein X is selected from NR7, S, O, S═O, and S(═O)2, wherein n is 0 or 1 and/or (c) R1 is an adamantyl group and Z is or comprises an amide group, and/or (d) R1 is an adamantyl group and Z is or comprises a group of the formula —(CR8R9)p- NR10—S(═O)2—(CR11R12)q-, wherein p is 0 or 1 and q is 0 or 1 and/or (e) R1 is an adamantyl group and Z is or comprises a group of the formula —(CR13R14)v-Y—(CR15R16)w- where Y is a heteroaryl group in which a bond in the heteroaryl ring is a isostere of a carbonyl group, wherein v is o or 1 and w is 0 or 1; wherein each of R3, R4, R5, R6, R8, R9, R11, R12, R13, R14, R15 and R16, are independently selected from H, hydrocarbyl and halogen, wherein each of R7 and R10 are independently selected from H and hydrocarbyl.
    • 提供了具有式I的化合物R1-Z-R2式Ⅰ其中R1是选自任选取代的稠合多环基团,取代的烷基,支链烷基和任选取代的环烷基的基团Z是一种或多种 羰基或羰基的等排基团选自任选取代的芳环和任选取代的杂环,其中(a)R 2是2-取代的噻吩基团,和/或(b)Z是式-C (= O)-CR 3 R 4 -X-(CR 5 R 6)n - ,其中X选自NR 7,S,O,S = O和S(= O)2,其中n为0或1和/或(c) R1是金刚烷基,Z是或包含酰胺基,和/或(d)R1是金刚烷基,Z是或包含式 - (CR8R9)对NR10-S(= O)2- (CR11R12)q-,其中p为0或1,q为0或1,和/或(e)R1为金刚烷基,Z为或包含式 - (CR13R14)vY-(CR15R16)w- 在哪里 Y是杂芳基环中的键是羰基的等离子体的杂芳基,其中v是0或1,w是0或1; 其中R 3,R 4,R 5,R 6,R 8,R 9,R 11,R 12,R 13,R 14,R 15和R 16各自独立地选自H,烃基和卤素,其中R 7和R 10各自独立地选自H和烃基 。
    • 4. 发明授权
    • Pharmaceutical compounds
    • US07132419B2
    • 2006-11-07
    • US11024759
    • 2004-12-30
    • John MiltonNigel VickerAdrian FolkesShouming WangWilliam Alexander Denny
    • John MiltonNigel VickerAdrian FolkesShouming WangWilliam Alexander Denny
    • C07D241/46A61K31/498
    • C07D403/12C07D241/46
    • A compound which is a benzo[a]phenazine-11-carboxamide derivative of formula (I) wherein each of R1 to R4, which are the same or different, is selected from hydrogen, halogen, hydroxyl, C1–C6 alkoxy which is unsubstituted or substituted, heteroaryloxy, C1–C6 alkyl which is unsubstituted or substituted, nitro, cyano, azido, amidoxime, CO2R10, CON(R12)2, OCON(R12), SR10, SOR11, SO2R11, SO2N(R12)2, N(R12)2, NR10SO2R11, N(SO2R11)2 NR10(CH2)nCN, NR10COR11, OCOR11 or COR10; each of R5 to R7, which are the same or different, is selected from hydrogen, halogen, hydroxy, C1–C6 alkoxy, C1–C6 alkyl, SR10 and N(R12)2; Q is C1–C6 alkylene which is unsubstituted or substituted by (i) C1–C6 alkyl which is unsubstituted or substituted, (ii) hydroxy, provided that the hydroxy group is not α to either of the N atoms adjacent to Q in formula (I), (iii) CO2R10, or (iv) CON(R12); R8 and R9, which are the same or different, are each hydrogen or C1–C6 alkyl, or R8 and R9 together with the nitrogen atom to which they are attached form a saturated 5- or 6-membered N-containing heterocyclic ring which may include one additional heteroatom selected from O, N and S, or one of R8 and R9 is an alkylene chain optionally interrupted by O, N or S, which is attached to a carbon atom on the alkylene chain represented by Q to complete a saturated 5- or 6-membered N-containing heterocyclic ring as defined above; R10 is hydrogen, C1–C6 alkyl, C3–C6 cycloalkyl, benzyl or phenyl; R11 is C1–C6 alkyl, C3–C6 cycloalkyl, benzyl or phenyl; each R12, which are the same or different, is hydrogen, C1–C6 alkyl cycloalkyl, benzyl or phenyl, or the two R12 groups form, together with the nitrogen atom to which they are attached a 5- or 6-membered saturated N-containing heterocyclic ring which may include 1 or 2 additional heteroatoms selected from O, N and S; and n is 1, 2 or 3; or a pharmaceutically acceptable salt thereof; with the proviso that at least one of R1 to R4 is other than hydrogen. These compounds are inhibitors of topoisomerase I and/or topoisomerase II and can be used to treat tumours, including tumours which express MDR.
    • 5. 发明申请
    • Pharmaceutical compounds
    • US20050143383A1
    • 2005-06-30
    • US11024759
    • 2004-12-30
    • John MiltonNigel VickerAdrian FolkesShouming WangWilliam Denny
    • John MiltonNigel VickerAdrian FolkesShouming WangWilliam Denny
    • C07D241/46C07D403/12A61K31/498C07D241/36
    • C07D403/12C07D241/46
    • A compound which is a benzo[a]phenazine-11-carboxamide derivative of formula (I) wherein each of R1 to R4, which are the same or different, is selected from hydrogen, halogen, hydroxyl, C1-C6 alkoxy which is unsubstituted or substituted, heteroaryloxy, C1-C6 alkyl which is unsubstituted or substituted, nitro, cyano, azido, amidoxime, CO2R10, CON(R12)2, OCON(R12), SR10, SOR11, SO2R11, SO2N(R12)2, N(R2)2, NR10SO2R11, N(SO2R11)2 NR10(CH2)nCN, NR10COR11, OCOR11 or COR10; each of R5 to R7, which are the same or different, is selected from hydrogen, halogen, hydroxy, C1-C6 alkoxy, C1-C6 alkyl, SR10 and N(R12)2; Q is C1-C6 alkylene which is unsubstituted or substituted by (i) C1-C6 alkyl which is unsubstituted or substituted, (II) hydroxy, provided that the hydroxy group is not α to either of the N atoms adjacent to Q in formula (I), (iii) CO2R10, or (iv) CON(R12); R8 and R9, which are the same or different, are each hydrogen or C1-C6 alkyl, or R8 and R9 together with the nitrogen atom to which they are attached form a saturated 5- or 6-membered N-containing heterocyclic ring which may include one additional heteroatom selected from O, N and S, or one of R8 and R9 is an alkylene chain optionally interrupted by O, N or S, which is attached to a carbon atom on the alkylene chain represented by Q to complete a saturated 5- or 6-membered N-containing heterocyclic ring as defined above; R10 is hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, benzyl or phenyl; R11 is C1-C6 alkyl, C3-C6 cycloalkyl, benzyl or phenyl; each R12, which are the same or different, is hydrogen, C1-C6 alkyl cycloalkyl, benzyl or phenyl, or the two R12 groups form, together with the nitrogen atom to which they are attached a 5- or 6-membered saturated N-containing heterocyclic ring which may include 1 or 2 additional heteroatoms selected from O, N and S; and n is 1, 2 or 3; or a pharmaceutically acceptable salt thereof; with the proviso that at least one of R1 to R4 is other than hydrogen. These compounds are inhibitors of topoisomerase I and/or topoisomerase II and can be used to treat tumours, including tumours which express MDR.
    • 6. 发明申请
    • COMPOUND CAPABLE OF INHIBITING 17-BETA HYDROXYSTERIOD DEHYDROGENASE
    • 抑制17-β羟化酶脱氢酶的化合物
    • US20100286204A1
    • 2010-11-11
    • US12744044
    • 2008-11-19
    • Nigel VickerHelen Victoria BaileyWesley HeatonJoanna Mary DayAtul PurohitBarry Victor Lloyd Potter
    • Nigel VickerHelen Victoria BaileyWesley HeatonJoanna Mary DayAtul PurohitBarry Victor Lloyd Potter
    • A61K31/4468C07C233/43A61K31/167C07D317/66A61K31/357C07D211/58C07D211/62A61K31/445C07C233/81C07D209/14A61K31/404C07D207/27A61K31/402A61P35/00
    • C07D207/26C07C217/90C07C233/43C07C237/42C07D211/58C07D211/62C07D317/66
    • There is provided a compound having Formula I wherein each of R1, R2, R3, R4, R5, R6, R7, R8 and R9 are independently selected from (a) H, (b) R13, —OC(R13)3, —OCH(R13)2, —OCH2R13, C(R13)3, —CH(R13)2, or —CH2R13 wherein R13 is a halogen; (c) —CN; (d) optionally substituted alkyl, (e) optionally substituted heteroalkyl; (f) optionally substituted aryl; (g) optionally substituted heteroaryl; (h) optionally substituted arylalkyl; (i) optionally substituted heteroarylalkyl; (j) hydroxy; (k) alkoxy; (l) aryloxy; (m) —SO2-alkyl; and (n) —N(R14)C(O)R15, wherein R14 and R15 are independently selected from H and hydrocarbyl, wherein the optional substituents of (d) (e) (f) (h) and (i) are selected from the group consisting of: C1-6 alkyl, halo, cyano, nitro, haloalkyl, hydroxy, C1-6 alkoxy, carboxy, carboxyalkyl, carboxamide, mercapto, amino, alkylamino, dialkylamino, sulfonyl, sulfonamido, aryl and heteroaryl; wherein n and p are independently selected from 0 and 1; X is an optional group selected from O, S, S=0, S(═O)2, C═O, S(═O)2NR16, C═ONR17, NR18, in which R16, R17, and R18 are independently selected from H and hydrocarbyl, R10 is selected from H and hydrocarbyl, R11 is selected from CR19R20 and C═O, in which R19 and R20 are independently selected from H and hydrocarbyl, R12 is selected from a substituted five or six membered carbon rings optionally containing one or more hetero atoms selected from N, S, and O and optionally having fused thereto a further ring, and wherein the one or more substituents are selected from hydrocarbyl groups.
    • 提供具有式I的化合物,其中R1,R2,R3,R4,R5,R6,R7,R8和R9各自独立地选自(a)H,(b)R13,-OC(R13)3, - OCH(R 13)2,-OCH 2 R 13,C(R 13)3,-CH(R 13)2或-CH 2 R 13,其中R 13是卤素; (c)-CN; (d)任选取代的烷基,(e)任选取代的杂烷基; (f)任选取代的芳基; (g)任选取代的杂芳基; (h)任选取代的芳基烷基; (i)任选取代的杂芳基烷基; (j)羟基; (k)烷氧基; (I)芳氧基; (m)-SO 2 - 烷基; 和(n)-N(R 14)C(O)R 15,其中R 14和R 15独立地选自H和烃基,其中选择(d)(e)(f)(h)和(i) 羟基,C 1-6烷氧基,羧基,羧基烷基,羧酰胺,巯基,氨基,烷基氨基,二烷基氨基,磺酰基,亚磺酰氨基,芳基和杂芳基; 其中n和p独立地选自0和1; X是选自O,S,S = 0,S(= O)2,C = O,S(= O)2 NR 16,C = CONR 17,NR 18的任选基团,其中R 16,R 17和R 18独立地选自 由H和烃基组成,R 10选自H和烃基,R 11选自CR 19 R 20和C = O,其中R 19和R 20独立地选自H和烃基,R 12选自取代的五或六元碳环,任选含有 一个或多个选自N,S和O的杂原子,并且任选地与另一个环稠合,并且其中一个或多个取代基选自烃基。
    • 10. 发明申请
    • Compound
    • 复合
    • US20060074060A1
    • 2006-04-06
    • US11234868
    • 2005-09-23
    • Nigel VickerHarshani LawrenceGillian AllanChristian BubertDelphine Sophie FischerAlan PurohitMichael ReedBarry Victor Potter
    • Nigel VickerHarshani LawrenceGillian AllanChristian BubertDelphine Sophie FischerAlan PurohitMichael ReedBarry Victor Potter
    • A61K31/58C07J71/00
    • C07J71/00C07J41/00
    • There is provided a compound of Formula (I) wherein (I) R2 is selected from (i) an alkyloxyalkyl group (ii) a nitrile group, and wherein R2 is capable of forming a hydrogen bond (iii) alkylaryl group, wherein the aryl group is substituted by other than a C1-10 group (iv) alkenylaryl group wherein the aryl group is substituted (v) alkylheteroaryl group, wherein when heteroaryl group comprises only C and N in the ring, the aryl group is substituted by other than a methyl group (vi) alkenylheteroaryl group, (vii) ═N—O-alkyl or ═N—O—H group (viii) branched alkenyl (ix) alkyl-alcohol group (x) amide or alkylamide wherein (a) the alkyl of the alkylamide is —CH2— or —Ch2Ch2—, (b) the amide is di-substituted and/or (c) the amide is substituted with at least one of alkyl heterocycle group, alkenyl heterocycle group, alkylheteroaryl group, alkenylheteroaryl group, heteroaryl group, alkylamine group, alkyloxyalkyl group, alkylaryl group, straight or branched alkyl group, (xi) —CHO so that R1 together with R3 provide the enol tautomer (a); OR R2 together with R3 form (xii) a pyrazole wherein (a) R4 is ═N—O-alkyl or ═N—O—H group, (b) the pyrazole is substituted with one of alkyl-OH group, alkyl ester group, alkyloxyalkyl group, branched alkyl group, and an amide and/or (c) the 2 position is substituted with a group selected from —OH and —O-hydrocarbyl (xiii) a heteroaryl ring to provide a compound of the formula (b); (II) R2 is selected from groups capable of forming a hydrogen bond, a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group and a sulphonamide group; and (III) R3 is selected from —OH, ═O, or a C(═O)—mimetic.
    • 提供式(I)化合物,其中(I)R 2选自(ⅰ)烷氧基烷基(ⅱ)腈基,其中R2能够形成氢键(ⅲ)烷基芳基,其中芳基 基团被取代的芳基(ⅴ)烷基杂芳基以外的C 1-10基团(ⅳ)链烯基芳基取代,其中当杂芳基仅在环中仅包含C和N时,芳基被除了 甲基(vi)烯基杂芳基,(vii)-NO-烷基或-NOH基(viii)支链烯基(ix)烷基 - 醇基(x)酰胺或烷基酰胺,其中(a)烷基酰胺的烷基是-CH2- 或-C 2 -C 12 - ,(b)酰胺是二取代的和/或(c)酰胺被烷基杂环基,烯基杂环基,烷基杂芳基,烯基杂芳基,杂芳基,烷基胺基,烷氧基烷基中的至少一个 基团,烷基芳基,直链或支链烷基,(xi)-CHO,使得R1起始 与R3提供烯醇互变异构体(a); OR 2与R 3一起形成(xii)吡唑,其中(a)R4是-NO-烷基或-NOH基,(b)吡唑被烷基-OH基,烷基酯基,烷氧基烷基,支链烷基 基团和酰胺和/或(c)2位被选自-OH和-O-烃基(xiii)杂芳基环的基团取代,以提供式(b)的化合物; (II)R2选自能够形成氢键的基团,氨基磺酸酯基,膦酸酯基,硫代膦酸酯基,磺酸酯基和磺酰胺基; 和(III)R 3选自-OH,-O或C(-O) - 模仿物。